An Australian-based unlisted biotech advancing a dual human-animal pipeline in oncology and wound healing using a proprietary biodiscovery platform. Its lead drug targets solid tumours via direct injection, showing pan-tumour activity in both veterinary and human clinical trials. The second asset is a topical agent for chronic and acute wounds, Read more ...
Tag: SmallMolecules
Project Region: Australia
Fund Stage: Mature / Pre-IPO
Problem and Solution:
Problem: Solid tumours and non-healing wounds continue to represent billion-dollar treatment gaps with limited targeted solutions and long development cycles.
Solution: A patented class of small molecules sourced from natural environments, designed to destroy tumours from within and accelerate wound recovery—already proven in animals and progressing in humans.
Project Region: Australia
Raise Size (Estimated in USD): 500K to 1M
